Multiparametric MRI for prostate cancer localization in correlation to whole‐mount histopathology

To prospectively evaluate multiparametric magnetic resonance imaging (MRI) for accurate localization of intraprostatic tumor nodules, with whole‐mount histopathology as the gold standard.

[1]  Guy Marchal,et al.  Multi-modality image registration by maximization of mutual information , 1996, Proceedings of the Workshop on Mathematical Methods in Biomedical Image Analysis.

[2]  Kyung Ah Kim,et al.  Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection--a multireader study. , 2009, Radiology.

[3]  John Kurhanewicz,et al.  Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. , 2009, European urology.

[4]  V. Mouraviev,et al.  Pathologic basis of focal therapy for early-stage prostate cancer , 2009, Nature Reviews Urology.

[5]  A. Prando.  Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume , 2009 .

[6]  Hyunjin Park,et al.  Registration methodology for histological sections and in vivo imaging of human prostate. , 2008, Academic radiology.

[7]  Thomas Hambrock,et al.  Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. , 2007, Radiology.

[8]  Rodolfo Montironi,et al.  Handling and pathology reporting of radical prostatectomy specimens. , 2003, European urology.

[9]  L. Kiemeney,et al.  Changes in prostate shape and volume and their implications for radiotherapy after introduction of endorectal balloon as determined by MRI at 3T. , 2009, International journal of radiation oncology, biology, physics.

[10]  Cher Heng Tan,et al.  Diffusion weighted imaging in prostate cancer , 2011, European Radiology.

[11]  Vincenzo Valentini,et al.  Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. , 2002, International journal of radiation oncology, biology, physics.

[12]  K. Taari,et al.  Optimal timing of post-biopsy MR imaging of the prostate , 2001 .

[13]  G. De Meerleer,et al.  Magnetic resonance imaging (MRI) anatomy of the prostate and application of MRI in radiotherapy planning. , 2007, European journal of radiology.

[14]  Guy Marchal,et al.  Multimodality image registration by maximization of mutual information , 1997, IEEE Transactions on Medical Imaging.

[15]  Jason A Koutcher,et al.  Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. , 2009, Radiology.

[16]  P. Scardino,et al.  A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. , 1991, The Journal of urology.

[17]  Masao Fukunaga,et al.  Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. , 2008, Radiology.

[18]  H. Hricak,et al.  Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. , 2007, International journal of radiation oncology, biology, physics.

[19]  Amita Shukla-Dave,et al.  Functional magnetic resonance imaging in prostate cancer. , 2009, European urology.

[20]  Filip Claus,et al.  Interobserver Delineation Variation Using CT versus Combined CT + MRI in Intensity–Modulated Radiotherapy for Prostate Cancer , 2005, Strahlentherapie und Onkologie.

[21]  D. Portalez,et al.  Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies , 2010, European Radiology.

[22]  M. Kattan,et al.  The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis , 2007, BJU international.

[23]  Tom W J Scheenen,et al.  IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. , 2006, International journal of radiation oncology, biology, physics.

[24]  H. Hricak,et al.  Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging. , 2009, Radiology.

[25]  Henkjan J Huisman,et al.  Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. , 2003, Radiology.

[26]  P. Choyke,et al.  Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. , 2010, Radiology.

[27]  Bruno Speleers,et al.  Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. , 2008, International journal of radiation oncology, biology, physics.

[28]  P. Carroll,et al.  Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. , 1995, Radiology.

[29]  Baris Turkbey,et al.  Imaging techniques for prostate cancer: implications for focal therapy , 2009, Nature Reviews Urology.

[30]  Aytekin Oto,et al.  Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. , 2010, Radiology.

[31]  Silvia D. Chang,et al.  Combined diffusion‐weighted and dynamic contrast‐enhanced MRI for prostate cancer diagnosis—Correlation with biopsy and histopathology , 2006, Journal of magnetic resonance imaging : JMRI.

[32]  François Cornud,et al.  Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2‐weighted, dynamic contrast‐enhanced and diffusion‐weighted imaging , 2011, BJU international.

[33]  P. Carroll,et al.  Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. , 2004, AJR. American journal of roentgenology.

[34]  K. Taari,et al.  Optimal timing of post-biopsy MR imaging of the prostate. , 2001, Acta radiologica.

[35]  Oguz Akin,et al.  Multimodality magnetic resonance imaging of prostate cancer. , 2010, Journal of endourology.

[36]  Marco van Vulpen,et al.  Validation of functional imaging with pathology for tumor delineation in the prostate. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  A. Evans,et al.  Prostate cancer detection with multi‐parametric MRI: Logistic regression analysis of quantitative T2, diffusion‐weighted imaging, and dynamic contrast‐enhanced MRI , 2009, Journal of magnetic resonance imaging : JMRI.

[38]  S. Webb,et al.  Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. , 2002, The British journal of radiology.

[39]  John E Tomaszewski,et al.  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era , 2002, Cancer.

[40]  B. K. Park,et al.  Comparison of Phased-Array 3.0-T and Endorectal 1.5-T Magnetic Resonance Imaging in the Evaluation of Local Staging Accuracy for Prostate Cancer , 2007, Journal of computer assisted tomography.

[41]  Yousef Mazaheri,et al.  MR imaging of the prostate in clinical practice , 2008, Magnetic Resonance Materials in Physics, Biology and Medicine.

[42]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[43]  Clare Allen,et al.  Dynamic contrast enhanced MRI in prostate cancer. , 2007, European journal of radiology.